Following President Trump’s Executive Order directing the Office of the Attorney General to expedite the process of rescheduling medical marijuana to Schedule III of the Controlled Substances Act (CSA), the U.S. Department of Justice has published the following regulatory actions in the Federal Register: 

1. A final rule placing both FDA-approved medical products containing marijuana and medical marijuana products regulated by a state medical marijuana license in Schedule III of the CSA.
2. A proposed rule withdrawing the prior administrative hearing process. 
3. A new notice of hearing, reinstating the formal evidentiary process required under the CSA.

 The process is being carried out through the formal rulemaking process, which includes public input, administrative review, and potential hearings.